Jozefa Wesierska-Gadek


Affiliation: Medical University of Vienna
Country: Austria


  1. request reprint
    Wesierska Gadek J, Maurer M. Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms. Curr Pharm Des. 2011;17:256-71 pubmed
  2. request reprint
    Wesierska Gadek J, Schreiner T, Maurer M, Waringer A, Ranftler C. Phenol red in the culture medium strongly affects the susceptibility of human MCF-7 cells to roscovitine. Cell Mol Biol Lett. 2007;12:280-93 pubmed
    ..We observed that phenol red added to the culture medium strongly promoted the cell proliferation and cell cycle progression of human cells expressing the estrogen receptor, and affected their susceptibility to chemotherapy. ..
  3. Wesierska Gadek J, Zulehner N, Ferk F, Składanowski A, Komina O, Maurer M. PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells. Biochem Pharmacol. 2012;84:1318-31 pubmed publisher
  4. request reprint
    Wesierska Gadek J, Schreiner T, Gueorguieva M, Ranftler C. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells. J Cell Biochem. 2006;98:1367-79 pubmed
    ..Therefore, the exposure of cancer patients to the estrogen mimics should be avoided at least during chemotherapy by CDK inhibitors. ..
  5. request reprint
    Wesierska Gadek J, Gueorguieva M, Kramer M, Ranftler C, Sarg B, Lindner H. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein. J Cell Biochem. 2007;102:1405-19 pubmed
    ..These results were subsequently confirmed by immunoblotting. Further experiments revealed that OLO, but not ROSC, strongly up-regulates CLIMP-63 in a dose- and time-dependent manner solely in senescent cells. ..
  6. Wesierska Gadek J, Krystof V. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?. Ann N Y Acad Sci. 2009;1171:228-41 pubmed publisher
    ..In this article the action and specificity of CDK inhibitor roscovitine, belonging to the group of purine analogues, is reviewed and the rationale for dissecting the inhibitory action on cell cycle and transcriptional CDKs is discussed. ..
  7. Wesierska Gadek J, Gritsch D, Zulehner N, Komina O, Maurer M. Interference with ER-? enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells. J Cell Biochem. 2011;112:1103-17 pubmed publisher
    ..Our results demonstrate that ROSC negatively affects the functional status of ER-?, making it potentially useful in the treatment of estrogen-dependent breast cancer cells. ..
  8. request reprint
    Wesierska Gadek J, Gueorguieva M, Horky M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther. 2005;4:113-24 pubmed
    ..Remarkably, roscovitine failed to induce phosphorylation at Ser46 in caspase-3-reconstituted MCF-7 cells. Our results indicate that, depending on the status of caspase-3 in MCF-7 cells, different apoptotic pathways were initialized. ..
  9. request reprint
    Wesierska Gadek J, Klima A, Komina O, Ranftler C, Invernizzi P, Penner E. Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies. Ann N Y Acad Sci. 2007;1109:519-30 pubmed
    ..Considering the recently reported clinical significance of ANAs in PBC, the prognostic value of the anti-NPC antibodies and their correlation with severity and progression of the disease is under evaluation...

More Information


  1. request reprint
    Wesierska Gadek J, Gueorguieva M, Komina O, Schmid G, Kramer M. Signaling of DNA damage is not sufficient to induce p53 response: (re)activation of wt p53 protein strongly depends on cellular context. J Cell Biochem. 2008;103:1607-20 pubmed
    ..This implicates that the capability of different agents to activate p53 in HeLaS(3) cells primarily depends on their inhibitory effect on expression of E6 oncoprotein. ..
  2. request reprint
    Wesierska Gadek J, Klima A, Ranftler C, Komina O, Hanover J, Invernizzi P, et al. Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen. J Cell Biochem. 2008;104:27-37 pubmed